Healthcare Professionals

Riptide Aspiration System

Aspiration Thrombectomy for
Acute Ischemic Stroke

  • Picture of Riptide Aspiration System

OVERVIEW

The Riptide™ Aspiration System is designed to retrieve a blood clot and restore blood flow to occluded vessels in the brain for patients experiencing acute ischemic stroke (AIS) due to a large vessel occlusion (LVO).

Dedicated to providing comprehensive solutions, Medtronic is committed to supporting physicians with more proven options for treating their patients with AIS. The Riptide Aspiration System expands our AIS product portfolio, empowering physicians with yet another valuable tool in the fight against stroke.

RIPTIDE ASPIRATION PUMP
RIPTIDE COLLECTION CANISTER AND INTERMEDIATE TUBING
RIPTIDE ASPIRATION TUBING
REACT™ 68 CATHETER

The Riptide Aspiration System features:

  • Low-cost disposables
  • Individually packaged consumables
  • Rapid ON/OFF feature
  • Large vacuum gauge
  • Multi-level dampeners to reduce vibration
  • Wide 10” handle
  • 450˚ rotational dial
  • Optional roll-stroke cart

STROKE ACCESS DEVICES

For information about related stroke access products:

MANUALS AND TECHNICAL GUIDES

Riptide Aspiration System Instructions for Use

This technical manual includes indications, warnings, precautions, product specifications, instructions, and clinical study summary. Find in the product labeling supplied with each device or call Medtronic at 800-961-9055.

MODEL SPECIFICATIONS

Download the model specifications sheet to use as a quick-reference guide for Riptide Aspiration System product details.

pdf Riptide Aspiration System (.pdf)

Model specs and ordering information for Riptide Aspiration System

337KB

Downloadable PDF of Model Specifications for Riptide Aspiration System

INDICATIONS

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.